Docteur ERIC DAHAN
✨ Profil synthétique
IA · 01/05/2026Le Docteur ERIC DAHAN est un rhumatologue exerçant à Marseille. Ses publications sur PubMed couvrent des sujets tels que les biothérapies non-anti-TNF, le lupus, le rhumatisme psoriasique et la maladie de Sjögren. Il a soutenu une thèse de doctorat en médecine.
Expertises présumées
- Biothérapies non-anti-TNF
- Lupus
- Rhumatisme psoriasique
- Sjögren
- Thérapeutiques biologiques
- Rhumatologie inflammatoire
- Maladies auto-immunes
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Thèses universitaires
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Localisation des cabinets
Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.
Lieux de consultation
CENTRE DE SANTE BOUCHARD
203 Rue BRETEUIL, 13006 Marseille 6e Arrondissement
☎ 0465400650Salarié (centre de santé)© OpenStreetMapCABINET DU DR ERIC DAHAN
CENTRE MEDICAL — 487 RUE JEAN QUEILLAU, 13014 Marseille
Libéral© OpenStreetMap
Tarifs & secteur de conventionnement
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases
Clinical rheumatology · 2013
📚 50 citations🎯 RCR 2.11Top 25% NIH - 2Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
Lupus science & medicine · 2022
Lire l'abstract Crossref ↓
Objective Among the most significant challenges in SLE are the excessive diagnosis delay and the lack of coordinated care. The aim of the study was to investigate patient pathways in SLE in order to improve clinical and organisational challenges in the management of those with suspected and confirmed SLE. Methods We conducted a cross-sectional study of patients with SLE, healthcare providers and other representative stakeholders. Focus groups were conducted, and based on the collected data the most impactful disruption points in SLE patient pathways were identified. A novel framework to improve individual patient pathways in SLE was developed, discussed and validated during a consensus meeting with representative stakeholders. Results Six thematic clusters regarding disruption in optimal patient pathways in SLE were identified: appropriate and timely referral strategy for SLE diagnosis; the need for a dedicated consultation during which the diagnosis of SLE would be announced, and following which clarifications and psychological support offered; individualised patient pathways with coordinated care based on organ involvement, disease severity and patient preference; improved therapeutic patient education; prevention of complications such as infections, osteoporosis and cancer; and additional patient support. During the consensus meeting, the broader panel of stakeholders achieved consensus on these attributes and a framework for optimising SLE patient pathways was developed. Conclusions We have identified significant disruption points and developed a novel conceptual framework to improve individual patient pathways in SLE. These data may be of valuable interest to patients with SLE, their physicians, health organisations as well as policy makers.
- 3[Paradoxical cutaneous reactions associated with tocilizumab therapy]
La Revue de medecine interne · 2014
📚 12 citations
Publications scientifiques (5) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Biothérapies non-anti-TNF2
▼
Biothérapies non-anti-TNF2
▼- [Paradoxical cutaneous reactions associated with tocilizumab therapy]
La Revue de medecine interne · 2014 · Case Reports
Sparsa L, Afif N, Bularca S, Fricker A, et al.
📚 12 cit.🔬→🩺 Translationnel - Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases
Clinical rheumatology · 2013 · Case Reports
Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, et al.
📚 50 cit.🎯 RCR 2.11🔬→🩺 Translationnel
Lupus1
▼
Lupus1
▼- Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
Lupus science & medicine · 2022 · Journal Article
Schlencker A, Messer L, Ardizzone M, Blaison G, et al.
📚 18 cit.🎯 RCR 2.38🔬→🩺 Translationnel
Rhumatisme psoriasique1
▼
Rhumatisme psoriasique1
▼- A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA)
Rheumatology (Oxford, England) · 2024 · Journal Article
Lioté F, Constantin A, Dahan É, Quiniou JB, et al.
📚 3 cit.🎯 RCR 1.12🔬→🩺 Translationnel
Sjögren1
▼
Sjögren1
▼- Not Just Sjögren's: A Rare Life-Threatening Manifestation in a Pediatric Patient
Cureus · 2025 · Case Reports
Dahan E, Cooley A, Ridgeway K, Fathalla B, et al.